Karyopharm Therapeutics Earnings Estimate
| KPTI Stock | USD 4.02 0.17 4.42% |
Karyopharm Therapeutics Revenue Breakdown by Earning Segment
By analyzing Karyopharm Therapeutics' earnings estimates, investors can diagnose different trends across Karyopharm Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. As of now, Karyopharm Therapeutics' Gross Profit is increasing as compared to previous years. The Karyopharm Therapeutics' current Gross Profit Margin is estimated to increase to 1.01, while Pretax Profit Margin is projected to decrease to (0.55).
Karyopharm | Build AI portfolio with Karyopharm Stock |
Karyopharm Therapeutics Earnings per Share Projection vs Actual
About Karyopharm Therapeutics Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Karyopharm Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Karyopharm Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Karyopharm Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -1.6 B | -1.5 B | |
| Retained Earnings Total Equity | -1.2 B | -1.1 B | |
| Earnings Yield | (0.93) | (0.88) | |
| Price Earnings Ratio | (1.08) | (1.13) | |
| Price Earnings To Growth Ratio | 0.02 | 0.02 |
Currently Active Assets on Macroaxis
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.49) | Revenue Per Share | Quarterly Revenue Growth (0.09) | Return On Assets | Return On Equity |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.